Advertisement

Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drug

  • Tamer Özülker
  • Filiz Özülker
  • Meral Mert
  • Tevfik Özpaçacı
Original Article

Abstract

Purpose

This study was done to determine whether interruption of metformin before 18F-FDG PET/CT imaging could prevent the increased 18F-FDG uptake in the intestine caused by this drug.

Methods

Included in the study were 41 patients with known type 2 diabetes mellitus who were referred to our department for evaluation of various neoplastic diseases. Patients underwent two 18F-FDG PET/CT scans, the first while they were on metformin and the second after they had stopped metformin. They stopped metformin and did not take any other oral antidiabetic medication starting 3 days before the second study and their blood glucose level was regulated with insulin when necessary to keep it within the range 5.55–8.33 mmol/l. FDG uptake was graded visually according to a four-point scale and semiquantitatively by recording the maximum standardized uptake value (SUVmax) in different bowel segments. A paired-samples t-test method was used to determine whether there was a significant difference between SUVmax measurements and visual analysis scores of the metabolic activity of the bowel in the PET/CT scans before and after stopping metformin.

Results

Diffuse and intense 18F-FDG uptake was observed in bowel segments of patients, and the activity in the colon was significantly decreased both visually and semiquantitatively in PET/CT scans performed after patients stopped metformin (p<0.05). There was a statistically significant decrease in activity in the small intestine on visual analysis (p<0.05), but semiquantitative measurements did not show a significant decrease in the SUVmax values in the duodenum or jejunum (p>0.05).

Conclusion

Metformin causes an increase in 18F-FDG uptake in the bowel and stopping metformin before PET/CT study significantly decreased this unwanted uptake, especially in the colon, facilitating the interpretation of images obtained from the abdomen and preventing the obliteration of lesions.

Keywords

Metformin 18F-FDG PET/CT Antidiabetic Bowel uptake 

Notes

Acknowledgments

We express special thanks to Mrs. Funda Sezgin for her help with the statistical analysis.

References

  1. 1.
    Bischof Delaloye A, Wahl RL. How high a level of FDG abdominal activity is considered normal?. J Nucl Med. 1995;36(suppl):106P. (abstract).Google Scholar
  2. 2.
    Nakada K, Fisher SJ, Brown RS, Wahl RL. FDG uptake in the gastrointestinal tract: can it be reduced? J Nucl Med 1999;40:22–3.Google Scholar
  3. 3.
    Stahl A, Weber WA, Avril N, Schwaiger M. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 2000;39:241–5.PubMedGoogle Scholar
  4. 4.
    Jadvar H, Schambye RB, Segall GM. Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. Clin Nucl Med 1999;24:965–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 2008;35:95–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998;23:3–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 1994;112:671–5.PubMedGoogle Scholar
  8. 8.
    Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol 2000;59:887–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol 1991;43:120–1.PubMedGoogle Scholar
  11. 11.
    Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol 1990;39:1831–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994;24:49–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992;105:1009–13.PubMedGoogle Scholar
  14. 14.
    Pénicaud L, Hitier Y, Ferré P, Girard J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 1989;262:881–5.PubMedGoogle Scholar
  15. 15.
    Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008;51:1552–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang W, Guan KL. AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 2009;196:55–63.CrossRefGoogle Scholar
  17. 17.
    Sanz P. AMP-activated protein kinase: structure and regulation. Curr Protein Pept Sci 2008;9:478–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Santomauro Júnior AC, Ugolini MR, Santomauro AT, Souto RP. Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome. Arq Bras Endocrinol Metabol 2008;52:120–5.PubMedGoogle Scholar
  19. 19.
    Roy FN, Beaulieu S, Boucher L, Bourdeau I, Cohade C. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med 2009;50:178–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Yasuda S, Takahashi W, Takagi S, Fujii H, Ide M, Shohtsu A. Factors influencing physiological FDG uptake in the intestine. Tokai J Exp Clin Med 1998;23:241–4.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Tamer Özülker
    • 1
    • 3
  • Filiz Özülker
    • 1
  • Meral Mert
    • 2
  • Tevfik Özpaçacı
    • 1
  1. 1.Department of Nuclear MedicineOkmeydani Training and Research HospitalİstanbulTurkey
  2. 2.Department of Internal MedicineOkmeydani Training and Research HospitalİstanbulTurkey
  3. 3.Darüşşafaka Mah. Gazeteciler SitesiMaslakTurkey

Personalised recommendations